The short answer
Melatonin may add to drowsiness or impairment with tapentadol. The exact pair’s sedation or breathing-risk increase has not been measured.
What this answer covers
Oral melatonin products with variable dose and release form.
- Supplement or preparation
- Melatonin
- Medication ingredient
- tapentadol
The supplement evidence is indirect
Daytime melatonin impaired performance in a small volunteer study; it did not test tapentadol.
Tapentadol can impair breathing and alertness
Its labels warn about serious effects with other CNS depressants. This supports caution with sedating supplements, but does not establish a particular supplement’s adverse-event rate.
Preparation and formulation matter
Use the exact supplement label in the review. Immediate- and extended-release tapentadol are different products; the extended-release tablet must stay intact.
Review before adding a sleep or calming product
Discuss co-use with the prescriber and avoid driving while impaired. Slow breathing or unusual difficulty waking requires emergency help. No short dosing gap has been shown to remove this risk.
Evidence and practical considerations
Side effects & toxicity
Conditional sedation precaution from exact tapentadol label and supplement-specific guidance/effects. No measured pair incidence; preparation and valerian-species limits retained.
- Exact scope
- Oral melatonin products with variable dose and release form. with Tapentadol RxCUI787390 IN supplied as HCl oral immediate-release or extended-release tablets.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed tapentadol
Opioid and noradrenergic analgesic actions; warnings for CNS-depressant combinations, serotonin syndrome with serotonergic drugs, and seizures in susceptible settings. Mainly glucuronidated; limited CYP metabolism.
How this applies: Exact tapentadol RxCUI 787390 IN, with stated salt/formulation/route bridge.
No herbal-pair risk rate. Immediate and extended release differ. General seizure warning does not establish a St John’s wort-specific seizure interaction.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed tapentadol
Opioid and noradrenergic analgesic actions; warnings for CNS-depressant combinations, serotonin syndrome with serotonergic drugs, and seizures in susceptible settings. Mainly glucuronidated; limited CYP metabolism.
How this applies: Exact tapentadol RxCUI 787390 IN, with stated salt/formulation/route bridge.
No herbal-pair risk rate. Immediate and extended release differ. General seizure warning does not establish a St John’s wort-specific seizure interaction.
Source 3: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Daytime drowsiness can occur; people with epilepsy need medical supervision when using melatonin.
How this applies: Original source interpreted for tapentadol only within the stated preparation and endpoint limits.
Not a direct tapentadol combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 16 healthy young adults.
Reaction, response and tracking performance worsened after daytime melatonin.
How this applies: Original source interpreted for tapentadol only within the stated preparation and endpoint limits.
Not a direct tapentadol combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact tapentadol article with formulation-specific evidence and uncertainty. | |
| Research summary published |
Article revision: de67f5bd2855851c
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.